Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Acquired Immunodeficiency Syndrome HELP
Based on 8,607 articles since 2006
||||

These are the 8607 published articles about Acquired Immunodeficiency Syndrome that originated from Worldwide during 2006-2015.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline [Consensus Statement by GeSIDA/National AIDS Plan Secretariat on antiretroviral treatment in adults infected by the human immunodeficiency virus (Updated January 2013)]. 2013

Anonymous2210763. · ·Enferm Infecc Microbiol Clin · Pubmed #24161378.

ABSTRACT: OBJECTIVE: This consensus document is an update of combined antiretroviral therapy (cART) guidelines for HIV-1 infected adult patients. METHODS: To formulate these recommendations a panel composed of members of the GeSIDA/National AIDS Plan Secretariat (Grupo de Estudio de Sida and the Secretaría del Plan Nacional sobre el Sida) reviewed the efficacy and safety advances in clinical trials, cohort and pharmacokinetic studies published in medical journals (PubMed and Embase) or presented in medical scientific meetings. The strength of the recommendations and the evidence which support them are based on a modification of the criteria of Infectious Diseases Society of America. RESULTS: cART is recommended in patients with symptoms of HIV infection, in pregnant women, in serodiscordant couples with high risk of transmission, in hepatitisB co-infection requiring treatment, and in HIV nephropathy. cART is recommended in asymptomatic patients if CD4 is <500cells/μl. If CD4 are >500cells/μl cART should be considered in the case of chronic hepatitisC, cirrhosis, high cardiovascular risk, plasma viral load >100.000 copies/ml, proportion of CD4 cells <14%, neurocognitive deficits, and in people aged >55years. The objective of cART is to achieve an undetectable viral load. The first cART should include 2 reverse transcriptase inhibitors (RTI) nucleoside analogs and a third drug (a non-analog RTI, a ritonavir boosted protease inhibitor, or an integrase inhibitor). The panel has consensually selected some drug combinations, for the first cART and specific criteria for cART in acute HIV infection, in tuberculosis and other HIV related opportunistic infections, for the women and in pregnancy, in hepatitisB or C co-infection, in HIV-2 infection, and in post-exposure prophylaxis. CONCLUSIONS: These new guidelines update previous recommendations related to first cART (when to begin and what drugs should be used), how to monitor, and what to do in case of viral failure or adverse drug reactions. cART specific criteria in comorbid patients and special situations are similarly updated.

2 Guideline Executive summary of the Consensus Document of GeSIDA and Spanish Secretariat for the National Plan on AIDS on combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2013). 2013

Anonymous2200763. · ·Enferm Infecc Microbiol Clin · Pubmed #24156952.

ABSTRACT: In the present update of the guidelines, a starting combination antiretroviral treatment (cART) is recommended in symptomatic patients, in pregnant women, in serodiscordant couples with a high risk of transmission, in patients co-infected with hepatitis B virus requiring treatment, and in patients with HIV-related nephropathy. Guidelines on cART are included in the event of a concurrent diagnosis of HIV infection with an AIDS-defining event. In asymptomatic naïve patients, cART is recommended if the CD4(+) lymphocyte count is <500cells/μL; if the CD4(+) lymphocyte count is >500cells/μL, cART can be delayed, although it may be considered in patients with liver cirrhosis, chronic infection due to hepatitis C virus, high cardiovascular risk, plasma viral load (PVL) >10(5)copies/mL, CD4(+) lymphocyte percentage <14%, cognitive impairment, and age >55 years. cART in naïve patients requires a combination of 3 drugs, and its aim is to achieve undetectable PVL. Treatment adherence plays a key role in sustaining a favorable response. cART can, and should be, changed if virological failure occurs, in order to return to undetectable PVL. Approaches to cART in acute HIV infection, in women, in pregnancy, in tuberculosis, and post-exposure prophylaxis are also examined.

3 Guideline Executive summary. Consensus statement of the National AIDS Plan Secretariat, Spanish Society of Emergency Medicine and AIDS Study Group of the Spanish Society of Infectious Diseases and Clinical Microbiology on Emergency and HIV Infection. 2013

Anonymous5410755. ·rpolor@msssi.es ·Enferm Infecc Microbiol Clin · Pubmed #23601917.

ABSTRACT: Emergency Services (ES) are the cornerstone of our health system and therefore it cannot remain indifferent to the HIV advances that have drastically changed the landscape of the disease, so, emergency specialist updating is not only necessary, it is also essential. The purpose of this paper is to support non-HIV specialist professionals in treating patients with urgent diseases resulting from HIV infection or related to it.

4 Guideline [The Spanish AIDS Study Group and Spanish National AIDS Plan (GESIDA/Secretaría del Plan Nacional sobre el Sida) recommendations for the treatment of tuberculosis in HIV-infected individuals (Updated January 2013)]. 2013

Rivero, Antonio / Pulido, Federico / Caylá, Joan / Iribarren, José A / Miró, José M / Moreno, Santiago / Pérez-Camacho, Inés / Anonymous5310765 / Anonymous5320765. ·Panel de Expertos del Grupo de estudio de Sida (GESIDA-SEIMC) y de la Secretaría del Plan Nacional sobre el Sida (SPNS); Unidad de Enfermedades Infecciosas, Hospital Universitario 1050 Reina Sofía-IMIBIC, Córdoba, España. Electronic address: ariveror@gmail.com. · ·Enferm Infecc Microbiol Clin · Pubmed #23541879.

ABSTRACT: This consensus document was prepared by an expert panel of the Grupo de Estudio de Sida (GESIDA [Spanish AIDS Study Group]) and the Plan Nacional sobre el Sida (PNS [Spanish National AIDS Plan]). The document updates current guidelines on the treatment of tuberculosis (TB) in HIV-infected individuals contained in the guidelines on the treatment of opportunistic infections published by GESIDA and PNS in 2008. The document aims to facilitate the management and treatment of HIV-infected patients with TB in Spain, and includes specific sections and recommendations on the treatment of drug-sensitive TB, multidrug-resistant TB, and extensively drug-resistant TB, in this population. The consensus guidelines also make recommendations on the treatment of HIV-infected patients with TB in special situations, such as chronic liver disease, pregnancy, kidney failure, and transplantation. Recommendations are made on the timing and initial regimens of antiretroviral therapy in patients with TB, and on immune reconstitution syndrome in HIV-infected patients with TB who are receiving antiretroviral therapy. The document does not cover the diagnosis of TB, diagnosis/treatment of latent TB, or treatment of TB in children. The quality of the evidence was evaluated and the recommendations graded using the approach of the Grading of Recommendations Assessment, Development and Evaluation Working Group.

5 Guideline Position statement on the use of antiretroviral therapy to reduce HIV transmission, January 2013: the British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA). 2013

Fidler, S / Anderson, J / Azad, Y / Delpech, V / Evans, C / Fisher, M / Gazzard, B / Gill, N / Lazarus, L / Lowbury, R / Orton, K / Osoro, B / Radcliffe, K / Smith, B / Churchill, D / Rogstad, K / Cairns, G. ·Imperial College London, London, UK. s.fidler@imperial.ac.uk · ·HIV Med · Pubmed #23489936.

ABSTRACT: -- No abstract --

6 Guideline The 2010 South African guidelines for the management of HIV and AIDS: a review. 2011

Rossouw, Theresa / Richter, Karin / Martin, Des / Avenant, Theuns / Spencer, David. ·Department of Family Medicine, University of Pretoria. theresa.rossouw@up.ac.za · ·S Afr Med J · Pubmed #21786723.

ABSTRACT: -- No abstract --

7 Guideline [Acquired immunodeficiency syndrome]. 2010

Anonymous3480672. · ·Rev Chilena Infectol · Pubmed #21046725.

ABSTRACT: -- No abstract --

8 Guideline [Acquired immunodeficiency syndrome]. 2010

Anonymous3460667. · ·Rev Chilena Infectol · Pubmed #20737127.

ABSTRACT: -- No abstract --

9 Guideline [AIDS Study Group/Spanish AIDS Plan consensus document on antiretroviral therapy in adults with human immunodeficiency virus infection (updated January 2010)]. 2010

Anonymous1800664 / Anonymous1810664. · ·Enferm Infecc Microbiol Clin · Pubmed #20554079.

ABSTRACT: OBJECTIVE: This consensus document is an update of antiretroviral therapy recommendations for adult patients with human immunodeficiency virus infection. METHODS: To formulate these recommendations a panel made up of members of the Grupo de Estudio de Sida (Gesida, AIDS Study Group) and the Plan Nacional sobre el Sida (PNS, Spanish AIDS Plan) reviewed the advances in the current understanding of the pathophysiology of human immunodeficiency virus (HIV) infection, the efficacy and safety of clinical trials, and cohort and pharmacokinetic studies published in biomedical journals or presented at scientific meetings. Three levels of evidence were defined according to the data source: randomized studies (level A), cohort or case-control studies (level B), and expert opinion (level C). The decision to recommend, consider or not to recommend ART was established in each situation. RESULTS: Currently, the treatment of choice for chronic HIV infection is the combination of three drugs of two different classes, including 2 nucleosides or nucleotide analogs (NRTI) plus 1 non-nucleoside (NNRTI) or 1 boosted protease inhibitor (PI/r), but other combinations are possible. Initiation of ART is recommended in patients with symptomatic HIV infection. In asymptomatic patients, initiation of ART is recommended on the basis of CD4 lymphocyte counts, plasma viral load and patient co-morbidities, as follows: 1) therapy should be started in patients with CD4 counts below 350 cells/microl; 2) When CD4 counts are between 350 and 500 cells/microl, therapy should be started in case of cirrhosis, chronic hepatitis C, high cardiovascular risk, HIV nephropathy, HIV viral load above 100,000 copies/ml, proportion of CD4 cells under 14%, and in people aged over 55; 3) Therapy should be deferred when CD4 are above 500 cells/microl, but could be considered if any of previous considerations concurs. Treatment should be initiated in case of hepatitis B requiring treatment and should be considered for reduce sexual transmission. The objective of ART is to achieve an undetectable viral load. Adherence to therapy plays an essential role in maintaining antiviral response. Therapeutic options are limited after ART failures but undetectable viral loads maybe possible with the new drugs even in highly drug experienced patients. Genotype studies are useful in these situations. Drug toxicity of ART therapy is losing importance as benefits exceed adverse effects. Criteria for antiretroviral treatment in acute infection, pregnancy and post-exposure prophylaxis are mentioned as well as the management of HIV co-infection with hepatitis B or C. CONCLUSIONS: CD4 cells counts, viral load and patient co-morbidities are the most important reference factors to consider when initiating ART in asymptomatic patients. The large number of available drugs, the increased sensitivity of tests to monitor viral load, and the ability to determine viral resistance is leading to a more individualized therapy approach in order to achieve undetectable viral load under any circumstances.

10 Guideline [Prevention of infectious diseases]. 2007

Alvarez Pasquín, M J / Batalla Martínez, C / Comín Bertrán, E / Gómez Marco, J J / Pericas Bosch, J / Pachón del Amo, I / Rufino González, J / Mayer Pujadas, M A / Martín Martín, S / Agustí Morató, M L / Puig Barberá, J / Anonymous1830600. ·Grupo de Prevención de Enfermedades Infecciosas. · ·Aten Primaria · Pubmed #19288697.

ABSTRACT: -- No abstract --

11 Guideline API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India. 2006

Gupta, S B / Pujari, S N / Joshi, S R / Patel, A K / Anonymous2230561. ·Central Railway Headquarters Hospital, Mumbai. · ·J Assoc Physicians India · Pubmed #16649742.

ABSTRACT: With rational use of antiretroviral therapy (ART), human immunodeficiency virus (HIV) infection has been transformed into a chronic manageable illness like diabetes and hypertension. These guidelines provide information on state of art, evidence based approach for use of ART in Indian context. When to initiate ART? Antiretroviral therapy is indicated for all symptomatic HIV infected persons regardless of CD4 counts and plasma viral load (PVL) levels. In asymptomatic patients, ART should be offered when the CD4 counts < 200/mm3 and should be considered in patients with CD4 counts between 200-250/mm3. Therapy is not recommended for patients with CD4 count more than 350/ mm3. Involvement of patient in all treatment decisions and assessing readiness is critical before initiating ART. What to start with? A non-nucleoside reverse transcriptase inhibitor (NNRTI) based regimen is recommended for antiretroviral naïve patients. The choice between nevirapine and efavirenz is based on differences in adverse events profiles; cost and availability of convenient fixed dose combinations and need for concomitant use of rifampicin. A backbone of 2-nucleoside reverse transcriptase inhibitors (NRTIs) is combined with the NNRTI. Various combinations and ART strategies not to be used in clinical practice has been enlisted. How to follow up? Recommendations have been made for baseline evaluation and monitoring of patients on ART. These include guidelines on laboratory and clinical evaluation. A plasma viral load at 6 months after initiation of first-line ART is strongly recommended. Yearly estimation of lipid profile has been recommended. How to identify and manage ART failure? The guidelines recognize the issue of identifying ART failure late if only CD4 counts are used for monitoring. In the absence of resistance testing various second-line regimens have been enlisted. A boosted protease inhibitor based regimen is recommended in this situation to be combined with 2-NRTIs. Special situations Recommendations have been made for use of ART in HIV-TB, HIV-HBV, and HIV-HCV co-infected patients. In patients with active TB and a CD4 count < 200/mm3, initiation of ART is recommended as soon as the anti-TB treatment is tolerated. Efavirenz is the only ARV drug, which can be safely used with rifampicin. In pregnancy use of single dose nevirapine for reducing risk of mother to child transmission of HIV is not recommended, because of the risk of development of resistance. For post-exposure prophylaxis taking ART treatment history of the source patient is crucial in designing an effective regimen.

12 Guideline UK Guideline for the use of post-exposure prophylaxis for HIV following sexual exposure. 2006

Fisher, Martin / Benn, Paul / Evans, Barry / Pozniak, Anton / Jones, Mike / Maclean, Suzie / Davidson, Oliver / Summerside, Jack / Hawkins, David / Anonymous4320556. ·Department of Genitourinary Medicine, Royal Sussex County Hospital, Brighton, UK. Martin.Fisher@bsuh.nhs.uk · ·Int J STD AIDS · Pubmed #16464267.

ABSTRACT: We present the British Association for Sexual Health and HIV (BASHH) guidelines for post-exposure prophylaxis after sexual exposure (PEPSE) to HIV. This document includes a review of the current data to support the use of PEPSE, considers how to calculate the risks of HIV infection after a potential exposure, and provides recommendations on when PEPSE would and would not be considered. Other areas included are the possible impact on sexual behaviour, cost-effectiveness, and issues relating to service provision. Throughout the document, consideration is given to the place of PEPSE within the broader context of HIV prevention strategies and sexual health.

13 Editorial The death of AIDS--expected or exaggerated? 2015

Anonymous1590910. · ·Lancet · Pubmed #26681275.

ABSTRACT: -- No abstract --

14 Editorial Assessing the Impact of Sexuality and HIV/AIDS Education in Africa. 2015

Okonofua, Friday. · ·Afr J Reprod Health · Pubmed #26506653.

ABSTRACT: -- No abstract --

15 Editorial The HIV epidemic can be stopped. 2015

Anonymous3830810. · ·Nature · Pubmed #26156336.

ABSTRACT: -- No abstract --

16 Editorial Opportunistic Infections and Mortality: Still Room for Improvement. 2015

Masur, Henry / Read, Sarah W. ·Critical Care Medicine Department, Clinical Center. · Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. ·J Infect Dis · Pubmed #26044290.

ABSTRACT: -- No abstract --

17 Editorial Men's heightened risk of AIDS-related death: the legacy of gendered HIV testing and treatment strategies. 2015

Dovel, Kathryn / Yeatman, Sara / Watkins, Susan / Poulin, Michelle. ·aUniversity of Colorado, Denver, Colorado bUniversity of Pennsylvania, Philadelphia, Pennsylvania cUniversity of California Los Angeles, Los Angeles, California dThe World Bank, Washington, District of Columbia, USA. · ·AIDS · Pubmed #26035315.

ABSTRACT: -- No abstract --

18 Editorial Blue marble health and "the big three diseases": HIV/AIDS, tuberculosis, and malaria. 2015

Hotez, Peter J. ·Department of Pediatrics and Molecular Virology and Microbiology, National School of Tropical Medicine, Baylor College of Medicine, Houston, TX, USA; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development, Houston, TX, USA; James A. Baker III Institute for Public Policy, Rice University, Houston, TX, USA; Department of Biology, Baylor University, Waco, TX, USA. Electronic address: hotez@bcm.edu. ·Microbes Infect · Pubmed #26003523.

ABSTRACT: -- No abstract --

19 Editorial Skill and art in an intolerant world: a brief commentary on the article by Paiva et al. 2015

Bastos, Francisco I. · ·Cad Saude Publica · Pubmed #25859711.

ABSTRACT: -- No abstract --

20 Editorial Monitoring treatment outcomes in patients with chronic disease: lessons from tuberculosis and HIV/AIDS care and treatment programmes. 2015

Harries, Anthony D / Kumar, Ajay M V / Karpati, Adam / Jahn, Andreas / Douglas, Gerald P / Gadabu, Oliver J / Chimbwandira, Frank / Zachariah, Rony. ·International Union against Tuberculosis and Lung Disease, Paris, France.; London School of Hygiene and Tropical Medicine, London, UK. · International Union Against Tuberculosis and Lung Disease, South-East Asia Regional Office, New Delhi, India. · International Union Against Tuberculosis and Lung Disease, North America Office, New York, NY, USA. · Department of HIV and AIDS, Ministry of Health, Lilongwe, Malawi.; ITECH, Malawi and University of Washington, Seattle, WA, USA. · Center for Health Informatics for the Underserved, University of Pittsburgh, Pittsburgh, PA, USA. · Baobab Health Trust, Lilongwe, Malawi. · Department of HIV and AIDS, Ministry of Health, Lilongwe, Malawi. · Medecins sans Frontieres, Medical Department, Operational Research Unit, Brussels Operational Centre, Luxembourg, Luxembourg. ·Trop Med Int Health · Pubmed #25779103.

ABSTRACT: -- No abstract --

21 Editorial US hospital preparedness for obstetrics patients with possible Ebola. 2015

Meaney-Delman, Dana / Koonin, Lisa M / Jamieson, Denise J. ·National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA. Electronic address: vmo0@cdc.gov. · Influenza Coordination Unit, Office of Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA. · Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA. ·Am J Obstet Gynecol · Pubmed #25656019.

ABSTRACT: -- No abstract --

22 Editorial Interferon fundamentals: a tribute to the scientific vision of G B Rossi. Editorial. 2015

Battistini, Angela / Coccia, Eliana M / Belardelli, Filippo. ·Istituto Superiore di Sanità, Roma, Italy. Electronic address: angela.battistini@iss.it. · Istituto Superiore di Sanità, Roma, Italy. ·Cytokine Growth Factor Rev · Pubmed #25578521.

ABSTRACT: -- No abstract --

23 Editorial The role of HIV-specific antibody-dependent cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu protein. 2015

Kramski, Marit / Stratov, Ivan / Kent, Stephen J. ·Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute of Infection and Immunity, Melbourne, Victoria, Australia. · ·AIDS · Pubmed #25396265.

ABSTRACT: There is growing interest in the role of anti-HIV antibody-dependent cellular cytotoxicity (ADCC) antibodies in the prevention and control of HIV infection. Passive transfer studies in macaques support a role for the Fc region of antibodies in assisting in the prevention of simian-human immunodeficiency virus (SHIV) infection. The Thai RV144 HIV-1 vaccine trial induced anti-HIV ADCC antibodies that may have played a role in the partial protection observed. Several observational studies support a role for ADCC antibodies in slowing HIV disease progression. However, HIV evolves to escape ADCC antibodies and chronic HIV infections causes dysfunction of effector cells such as natural killer (NK) cells that mediate the ADCC functions. Further, four recent studies show that the HIV-1 Vpu protein, by promoting release of virions, reduces the capacity of ADCC antibodies to recognize HIV-infected cells. The review dissects some of the recent research on HIV-specific ADCC antibodies and discusses mechanisms to further harness ADCC antibodies in the prevention and control of HIV infection.

24 Editorial Biomedical HIV prevention research and development in Africa. 2014

Dada, Olukayode A. · ·Afr J Reprod Health · Pubmed #26050371.

ABSTRACT: -- No abstract --

25 Editorial After 3 decades of paediatric HIV/AIDS--where do we stand? 2014

Lala, M M / Merchant, R H. ·Pediatric HIV Telemedicine - Pediatric Centre of Excellence for HIV Care - LTMMC & LTMGH; Committed Communities Development Trust (CCDT), Mumbai Smiles, Society for Human & Environmental Development (SHED); Bai Jerbai Wadia Hospital for Children, Nowrosjee Wadia Maternity Hospital, Mumbai 400 050, India. · ·Indian J Med Res · Pubmed #25758566.

ABSTRACT: -- No abstract --

Next